0.01 0 (0%) | 02-12 15:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 0.06 | 1-year : | 0.1 |
Resists | First : | 0.05 | Second : | 0.08 |
Pivot price | 0 ![]() |
|||
Supports | First : | 0 | Second : | 0 |
MAs | MA(5) : | 0 | MA(20) : | 0 ![]() |
MA(100) : | 0 ![]() |
MA(250) : | 0.27 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 46.7 | D(3) : | 46.7 |
RSI | RSI(14): 51.8 | |||
52-week | High : | 2.47 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AMPE ] has closed below upper band by 23.5%. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.02 - 0.02 | 0.02 - 0.02 |
Low: | 0.01 - 0.01 | 0.01 - 0.01 |
Close: | 0.01 - 0.01 | 0.01 - 0.01 |
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Mon, 25 Mar 2024
Ampio Announces Voluntary Delisting and SEC Deregistration - PR Newswire
Thu, 11 Jan 2024
Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions - PR Newswire
Thu, 05 Oct 2023
Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201 - PR Newswire
Thu, 31 Aug 2023
Ampio Pharmaceuticals Announces Reverse Stock Split - PR Newswire
Tue, 29 Nov 2022
Investors who lost Money with shares of Ampio - GlobeNewswire
Mon, 17 Jun 2019
Ampio Pharmaceuticals Announces Pricing of Public Offering - BioSpace
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
AMEX
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 1 (M) |
Shares Float | 1 (M) |
Held by Insiders | 1.5 (%) |
Held by Institutions | 0 (%) |
Shares Short | 33 (K) |
Shares Short P.Month | 35 (K) |
EPS | -10.66 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 4.03 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -61.6 % |
Return on Equity (ttm) | -114 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -8.24 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -9 (M) |
Levered Free Cash Flow | -5 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | -0.01 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |